Use of VEGF-C agonists for inhibiting ultraviolet B-induced skin damage
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/18
A61K-008/64
A61Q-019/00
C07K-016/22
G01N-033/68
A61K-038/17
A61K-039/00
출원번호
US-0739533
(2013-01-11)
등록번호
US-9192652
(2015-11-24)
발명자
/ 주소
Detmar, Michael
Kajiya, Kentaro
출원인 / 주소
The General Hospital Corporation
대리인 / 주소
Fish & Richardson P.C.
인용정보
피인용 횟수 :
0인용 특허 :
14
초록
This application features methods of inhibiting ultraviolet B-induced skin damage in a subject. The methods include administering a VEGF-C agonist to the subject.
대표청구항▼
1. A method of reducing ultraviolet B (UVB)-induced damage to lymph vessels in skin of a subject, the method comprising: (a) selecting a subject with UVB-induced damage to lymph vessels in the skin;(b) topically, intramuscularly, intraperitoneally, subcutaneously, or intravenously administering to t
1. A method of reducing ultraviolet B (UVB)-induced damage to lymph vessels in skin of a subject, the method comprising: (a) selecting a subject with UVB-induced damage to lymph vessels in the skin;(b) topically, intramuscularly, intraperitoneally, subcutaneously, or intravenously administering to the selected subject a composition comprising a VEGF-C agonist in an amount sufficient to promote lymphatic function in the skin of the subject, wherein the promotion of lymphatic function in the skin of the subject reduces UVB-induced damage to lymph vessels in the skin of the subject. 2. The method of claim 1, wherein the subject is a human. 3. The method of claim 1, wherein the composition is administered to the subject prior to additional UVB-light exposure. 4. The method of claim 1, wherein the composition is administered to the subject during subsequent UVB light exposure. 5. The method of claim 1, wherein the composition is topically administered to the subject. 6. The method of claim 1, wherein the VEGF-C agonist is a VEGF-C polypeptide or a biologically active fragment thereof. 7. The method of claim 1, wherein the composition further comprises a carrier. 8. The method of claim 7, wherein the carrier is a pharmaceutically acceptable vehicle, lubricant, disintegrator, or binder. 9. The method of claim 7, wherein the carrier is a liposome suitable for topical delivery. 10. The method of claim 9, wherein the liposome is a lecithin liposome or an alkylphospholipid liposome. 11. The method of claim 7, wherein the carrier is a polyethylene glycol. 12. The method of claim 1, wherein the composition further comprises a moisturizer, a sunscreen, or both. 13. The method of claim 1, wherein the composition further comprises a preservative or fragrance. 14. The method of claim 1, wherein the composition is formulated in combination with a controlled release device. 15. The method of claim 14, wherein the controlled release device is a biocompatible polymer, microparticle, or mesh. 16. The method of claim 1, wherein the composition is formulated as a solution, cream, ointment, gel, lotion, shampoo, soap, or aerosol. 17. The method of claim 1, wherein the damage to lymph vessels in the skin comprises enlargement, leakiness, or both enlargement and leakiness of cutaneous lymphatic vessels.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (14)
Romero, Mónica Bequet; Acevedo Castro, Boris Ernesto; Gavilondo Cowley, Jorge Victor; Fernández Molina, Luis Enrique; Ocejo, Omar Lopez; Silva Rodriguez, Ricardo de la Caridad; Lasa, Alexis Musachio; Rodriguez, Ernesto Galban; Vázquez Blomquist, Dania Marcia, Active antiangiogenic therapy.
Achen, Marc; Stacker, Steven, Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.